Royalty Pharma (RPRX) Stock Analysis

What Royalty Pharma does

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Key metrics

ETFs linked to RPRX

Broad-market and Healthcare sector ETFs an investor holding Royalty Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RPRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Royalty Pharma?

Royalty Pharma trades under the ticker RPRX on NASDAQ.

Which exchange is RPRX listed on?

RPRX is listed on NASDAQ.

What sector does Royalty Pharma operate in?

Royalty Pharma is classified in the Healthcare sector (Medical - Pharmaceuticals industry).

How can PortView help analyze RPRX in a portfolio?

PortView shows RPRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.